252 related articles for article (PubMed ID: 12938280)
21. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
23. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
25. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
[No Abstract] [Full Text] [Related]
26. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
27. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
29. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
30. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
Tefferi A; Kantarjian H
Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
[No Abstract] [Full Text] [Related]
31. Imatinib mesylate--a new oral targeted therapy.
Savage DG; Antman KH
N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
[No Abstract] [Full Text] [Related]
32. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Deininger MW
J Cancer Res Clin Oncol; 2004 Feb; 130(2):59-72. PubMed ID: 14605878
[TBL] [Abstract][Full Text] [Related]
33. Imatinib mesylate.
Baker DE
Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
[TBL] [Abstract][Full Text] [Related]
34. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology of imatinib (STI571).
Buchdunger E; O'Reilly T; Wood J
Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate in children and adolescents with cancer.
Barr RD
Pediatr Blood Cancer; 2010 Jul; 55(1):18-25. PubMed ID: 20486169
[TBL] [Abstract][Full Text] [Related]
37. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Ren R
Nat Rev Cancer; 2005 Mar; 5(3):172-83. PubMed ID: 15719031
[TBL] [Abstract][Full Text] [Related]
39. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
Michor F
Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
[TBL] [Abstract][Full Text] [Related]
40. Current clinical management of gastrointestinal stromal tumors.
Tosoni A; Nicolardi L; Brandes AA
Expert Rev Anticancer Ther; 2004 Aug; 4(4):595-605. PubMed ID: 15270663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]